Literature DB >> 19361865

Prevalence and comorbidity of common mental disorders in primary care.

M Roca1, M Gili, M Garcia-Garcia, J Salva, M Vives, J Garcia Campayo, A Comas.   

Abstract

OBJECTIVE: To estimate the prevalence and comorbidity of the most common mental disorders in primary care practice in Spain, using the Primary Care Evaluation of Mental Disorders (PRIME-MD) questionnaire.
DESIGN: A systematic sample of 7936 adult primary care patients was recruited by 1925 general practitioners in a large cross-sectional national epidemiological study. The PRIME-MD was used to diagnose psychiatric disorders.
SETTING: 1356 primary care units proportionally distributed throughout the country.
RESULTS: 53.6% of the sample presented one or more psychiatric disorder. The most prevalent were affective (35.8%), anxiety (25.6%), and somatoform (28.8%) disorders. 30.3% of the patients had more than one current mental disorder. 11.5% presented comorbidity between affective, anxiety, and somatoform disorders.
CONCLUSIONS: The study provides further evidence of the high prevalence and high comorbidity of mental disorders in primary care. Given the large overlap between affective, anxiety and somatoform disorders, future diagnostic classifications should reconsider the current separation between these entities.

Entities:  

Mesh:

Year:  2009        PMID: 19361865     DOI: 10.1016/j.jad.2009.03.014

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  76 in total

Review 1.  Joint hypermobility and anxiety: the state of the art.

Authors:  Javier Garcia-Campayo; Elena Asso; Marta Alda
Journal:  Curr Psychiatry Rep       Date:  2011-02       Impact factor: 5.285

Review 2.  Somatoform disorders and medically unexplained symptoms in primary care.

Authors:  Heidemarie Haller; Holger Cramer; Romy Lauche; Gustav Dobos
Journal:  Dtsch Arztebl Int       Date:  2015-04-17       Impact factor: 5.594

3.  Specifying child anxiety disorders not otherwise specified in the DSM-IV.

Authors:  Jonathan S Comer; Kaitlin P Gallo; Priya Korathu-Larson; Donna B Pincus; Timothy A Brown
Journal:  Depress Anxiety       Date:  2012-07-16       Impact factor: 6.505

4.  Psychodynamic therapies versus other psychological therapies for depression.

Authors:  Rachel Churchill; Theresa Hm Moore; Philippa Davies; Deborah Caldwell; Hannah Jones; Glyn Lewis; Vivien Hunot
Journal:  Cochrane Database Syst Rev       Date:  2010

5.  Psychodynamic therapies versus treatment as usual for depression.

Authors:  Theresa Hm Moore; Vivien Hunot; Philippa Davies; Deborah Caldwell; Hannah Jones; Glyn Lewis; Rachel Churchill
Journal:  Cochrane Database Syst Rev       Date:  2010

6.  Humanistic therapies versus other psychological therapies for depression.

Authors:  Rachel Churchill; Philippa Davies; Deborah Caldwell; Theresa Hm Moore; Hannah Jones; Glyn Lewis; Vivien Hunot
Journal:  Cochrane Database Syst Rev       Date:  2010

7.  Interpersonal, cognitive analytic and other integrative therapies versus other psychological therapies for depression.

Authors:  Vivien Hunot; Theresa Hm Moore; Deborah Caldwell; Philippa Davies; Hannah Jones; Glyn Lewis; Rachel Churchill
Journal:  Cochrane Database Syst Rev       Date:  2010

8.  Humanistic therapies versus treatment as usual for depression.

Authors:  Philippa Davies; Vivien Hunot; Theresa Hm Moore; Deborah Caldwell; Hannah Jones; Glyn Lewis; Rachel Churchill
Journal:  Cochrane Database Syst Rev       Date:  2010

9.  Prevalence, types and comorbidity of mental disorders in a Kenyan primary health centre.

Authors:  Jean-Louis Aillon; David M Ndetei; Lincoln Khasakhala; Washington Njogu Ngari; Hesbon Otieno Achola; Selestine Akinyi; Simone Ribero
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-08       Impact factor: 4.328

10.  Assessing medically unexplained symptoms: evaluation of a shortened version of the SOMS for use in primary care.

Authors:  Cristina Fabião; M C Silva; António Barbosa; Manuela Fleming; Winfried Rief
Journal:  BMC Psychiatry       Date:  2010-05-17       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.